Abeta deposition and accumulation in the brain is hypothesized to trigger a complex pathological cascade leading to Alzheimer's diseases (AD). The current proposal will examine the efficacy of in situ CNS expression of anti-amyloid and anti-Abeta antibodies and single chain variable fragments (scFvs) with respect to attenuating AD-like pathologies present in APP mouse models. These studies will provide additional insight into proposed mechanisms relevant to the efficacy of anti-Abeta immunotherapy. By determining if selective targeting of fibrillar conformations of Abeta is more effective then targeting Abeta monomer, such studies may provide the scientific rationale for the development of novel forms of immunotherapy for AD. We will determine whether targeting of fibrillar Abeta amyloid as opposed to soluble monomeric Abeta is protective against development of AD-like pathologies in APP mouse models and whether antibodies targeting Abeta or Abeta amyloid are more effective then scFvs when expressed directly in the brain. We will also examine whether increased CNS expression of an efficacious anti-A? scFv enhances efficacy. Finally, we will use membrane tethered anti-Abeta and anti-amyloid scFvs to distinguish site or sties of action of anti-Abeta antibodies. By expressing membrane tethered scFvs in the brain we will determine if transport of scFvs out of the brain is required for efficacy. By expressing membrane tethered anti-Abeta or anti-amyloid scFvs in the liver we will attempt to definitively test the peripheral sink hypothesis (i.e., whether binding Abeta in the periphery is sufficient to enhance efflux from the brain and reduce Abeta deposition). We propose four specific aims that will utilize the power of recombinant adenoassociated viral vectors (rAAV) and the """"""""somatic brain transgenic technology"""""""" to express recombinant antibodies/scFvs in the brain and periphery. Abeta deposition and accumulation in the brain is hypothesized to trigger a complex pathological cascade leading to Alzheimer's diseases (AD). A number of preclinical studies have shown that targeting Abeta using immunological approaches may be of benefit in humans with AD. Based on data we have generated in the past several years, we believe that a more optimal approach is to target fibrillar conformations of Abeta as opposed to Abeta monomer. We have developed a novel technology platform that enables us to use recombinant antibody fragments to selectivity target Abeta amyloid as opposed to Abeta itself. These studies may provide the scientific rationale for the development of novel forms of immunotherapy for AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG018454-11
Application #
8230554
Study Section
Clinical Neuroimmunology and Brain Tumors Study Section (CNBT)
Program Officer
Refolo, Lorenzo
Project Start
2000-08-15
Project End
2013-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
11
Fiscal Year
2012
Total Cost
$285,786
Indirect Cost
$90,710
Name
University of Florida
Department
Neurosciences
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Rosario, Awilda M; Cruz, Pedro E; Ceballos-Diaz, Carolina et al. (2016) Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol Ther Methods Clin Dev 3:16026
Levites, Yona; O'Nuallain, Brian; Puligedda, Rama Devudu et al. (2015) A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo. J Neurosci 35:6265-76
Fernandez-Funez, Pedro; Zhang, Yan; Sanchez-Garcia, Jonatan et al. (2015) Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease. Hum Mol Genet 24:6093-105
Chakrabarty, Paramita; Li, Andrew; Ceballos-Diaz, Carolina et al. (2015) IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85:519-33
Ayers, Jacob I; Fromholt, Susan; Sinyavskaya, Olga et al. (2015) Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice. Mol Ther 23:53-62
Li, Andrew; Ceballos-Diaz, Carolina; DiNunno, Nadia et al. (2015) IFN-γ promotes τ phosphorylation without affecting mature tangles. FASEB J 29:4384-98
Chu, Jin; Li, Jian-Guo; Ceballos-Diaz, Carolina et al. (2013) The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence. Biol Psychiatry 74:321-8
Chu, Jin; Giannopoulos, Phillip F; Ceballos-Diaz, Carolina et al. (2012) 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol 72:442-54
Chu, Jin; Giannopoulos, Phillip F; Ceballos-Diaz, Carolina et al. (2012) Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol Neurodegener 7:1
Cai, Jun; Qi, Xiaoping; Kociok, Norbert et al. (2012) β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med 4:980-91

Showing the most recent 10 out of 24 publications